管理層內部使用該等指標進行規劃、預測和衡量本集團的整體表現。本集團認為該經調整財務指標為我們及投資者提供有用且有意義的資料，因為其提升投資者對本集團業務持續經營表現及便于比較過去和未來期間的業績。該等經調整財務指標為非GAAP指標應被視為附加于而不是替代根據GAAP<\/span>原則編制的資料。其他公司可能以其他方法定義該等指標。<\/p> \n

不包括融資活動的調整后的集團凈現金流：<\/i>本集團將期內短期投資變動計入期內現金及現金等價物變動，并扣除期內融資活動（所得）\/所用的現金凈額以計算出不包括融資活動的調整后的集團凈現金流。本集團認為，不包括融資活動的調整后的集團凈現金流的呈列就有關在扣除可能存在重大期間差異的融資活動現金流量后的資金資源使用提供有用及有意義的資料。<\/p> \n

固定匯率：<\/i>我們使用上年度的外幣匯率轉換本年度的業績進行逐年比較，以消除匯率變化對業績的影響。因為我們在中國經營著重要的業務，故人民幣兌美元的匯率變化可能對我們宣布的業績擁有重大影響。本集團認為<\/span>，展示以固定匯率計算的業績提供了有用且有意義的信息，這有助于促進逐年比較并提高我們基本業績的透明度。<\/p> \n

現金、現金等價物及短期投資的公認會計原則變動與不包括融資活動的調整后的集團凈現金流的調節：<\/b><\/p> \n

\n \n \n \n \n \n \n \n
百萬美元<\/span><\/p> <\/td> \n

<\/td> \n
2020<\/b>年<\/b><\/span><\/p> <\/td> \n
2019<\/b>年<\/b><\/span><\/p> <\/td> \n <\/tr> \n
年末現金、現金等價物及短期投資<\/span><\/p> <\/td> \n

<\/td> \n
435.2<\/span><\/p> <\/td> \n
217.2<\/span><\/p> <\/td> \n <\/tr> \n
     減: 年初現金、現金等價物及短期投資<\/span><\/p> <\/td> \n

<\/td> \n
(217.2)<\/span><\/p> <\/td> \n
(301.0)<\/span><\/p> <\/td> \n <\/tr> \n
減: 年內融資活動（所得）\/所用的現金流量凈額<\/span><\/p> <\/td> \n

<\/td> \n
(296.4)<\/span><\/p> <\/td> \n
1.5<\/span><\/p> <\/td> \n <\/tr> \n
不包括融資活動的調整后的集團凈現金流量凈額<\/span><\/p> <\/td> \n

<\/td> \n
(78.4)<\/span><\/p> <\/td> \n
(82.3)<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
GAAP<\/span>原則下的收入及和黃醫藥應占其他業務凈溢利變動率相對于固定匯率變動率的調節:<\/b><\/p> \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
百萬美元 (除%外)<\/span><\/p> <\/td> \n
截至<\/b>12<\/b>月<\/b>31<\/b>日<\/b>止年度<\/b><\/span><\/p> <\/td> \n

<\/td> \n
變動金額<\/b><\/span><\/p> <\/td> \n

<\/td> \n
變動率<\/b>%<\/b><\/span><\/p> <\/td> \n <\/tr> \n
2020<\/b>年<\/b><\/span><\/p> <\/td> \n
2019<\/b>年<\/b><\/span><\/p> <\/td> \n

<\/td> \n
實際<\/b><\/span><\/p> <\/td> \n
固定匯率<\/b><\/span><\/p> <\/td> \n
匯率影響<\/b><\/span><\/p> <\/td> \n

<\/td> \n
實際<\/b> <\/b><\/span><\/p> <\/td> \n
固定匯率<\/b><\/span><\/p> <\/td> \n
匯率影響<\/b><\/span><\/p> <\/td> \n <\/tr> \n
綜合收入— 其他業務<\/span><\/p> <\/td> \n
197.8<\/b><\/span><\/p> <\/td> \n
178.1<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/p>
19.7<\/b><\/span><\/p> <\/td> \n
<\/p>
20.5<\/b><\/span><\/p> <\/td> \n
<\/p>
(0.8)<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/p>
11%<\/b><\/span><\/p> <\/td> \n
<\/p>
11%<\/b><\/span><\/p> <\/td> \n
<\/p>
0%<\/b><\/span><\/p> <\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
和黃醫藥應占綜合凈溢利<\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
不包括白云山和黃中藥的一次<\/span><\/p>
性土地收儲補償收益<\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
<\/b>其他業務<\/b><\/span><\/p> <\/td> \n
44.0<\/b><\/span><\/p> <\/td> \n
41.5<\/b><\/span><\/p> <\/td> \n

<\/td> \n
2.5<\/b><\/span><\/p> <\/td> \n
3.3<\/b><\/span><\/p> <\/td> \n
(0.8)<\/b><\/span><\/p> <\/td> \n

<\/td> \n
6%<\/b><\/span><\/p> <\/td> \n
8%<\/b><\/span><\/p> <\/td> \n
-2%<\/b><\/span><\/p> <\/td> \n <\/tr> \n
   — 并表附屬公司<\/span><\/p> <\/td> \n
2.8<\/span><\/p> <\/td> \n
2.9<\/span><\/p> <\/td> \n

<\/td> \n
(0.1)<\/span><\/p> <\/td> \n
(0.1)<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
-5%<\/span><\/p> <\/td> \n
-5%<\/span><\/p> <\/td> \n
0%<\/span><\/p> <\/td> \n <\/tr> \n
   — 非并表合資企業<\/span><\/p> <\/td> \n
41.2<\/span><\/p> <\/td> \n
38.6<\/span><\/p> <\/td> \n

<\/td> \n
2.6<\/span><\/p> <\/td> \n
3.4<\/span><\/p> <\/td> \n
(0.8)<\/span><\/p> <\/td> \n

<\/td> \n
7%<\/span><\/p> <\/td> \n
9%<\/span><\/p> <\/td> \n
-2%<\/span><\/p> <\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
土地收儲補償收益<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
— 白云山和黃中藥<\/span><\/p> <\/td> \n
28.8<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
28.8<\/span><\/p> <\/td> \n
28.8<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
-<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
參考資料和簡稱<\/b><\/p> \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
[1]<\/b> 由禮來開具發票的愛優特^{®<\/sup>對第三方的銷售額為3,270萬美元（2019年：1,760萬元）及由和黃醫藥開具發票的對第三方的銷售額為100萬美元（2019年：無）<\/i><\/span><\/p> <\/td> \n <\/tr> \n}
[2]<\/b> 禮來 = 禮來公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[3]<\/b> MET = 間充質上皮轉化因子<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[4]<\/b> MAPK = RAS-RAF-MEK-ERK信號通路<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[5]<\/b> ERK = 細胞外信號調節激酶<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[6]<\/b> VEGFR = 血管內皮生長因子受體<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[7]<\/b> FGFR = 成纖維細胞生長因子受體<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[8]<\/b> CSF-1R = 集落刺激因子-1受體<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[12]<\/b> 君實生物 = 上海君實生物醫藥科技股份有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[13]<\/b> PD-1 = 程序性死亡受體1<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[14]<\/b> 百濟神州 = 百濟<\/span>神州有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[15]<\/b> IDMC = 獨立數據監察委員會<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[16]<\/b> 信達生物 = 信達生物制藥（蘇州）有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[19]<\/b> EGFR = 表皮生長因子受體<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[20]<\/b> PI3Kδ = 磷脂酰肌醇3-激酶亞型δ<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[21]<\/b> Syk = 脾酪氨酸激酶<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[22]<\/b> FGFR2 = 成纖維細胞生長因子受體2<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[23]<\/b> IDH1\/2 = 異檸檬酸脫氫酶1\/2<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[24]<\/b> 白云山和黃中藥 = 廣州白云山和記黃埔中藥有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[25]<\/b> GAAP = 美國公認會計原則<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[26]<\/b> 本年度報告中提及的按照固定匯率報告的財務指標均是基于非GAAP財務指標。請參閱下文“非GAAP財務指標的使用和調節” ，以分別了解與這些財務指標的解釋，以及這些財務指標與最具可比性的GAAP指標的對賬。<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[27]<\/b> 其他項目 = 包括其他收入、所得稅費用、權益性被投資企業盈利中的權益（扣除稅款）和歸屬于非控制性權益的凈收入<\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>